pembrolizumab
( PEM broe LIZ ue mab )
Other Name(s): Keytruda®
Appearance: solution
mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Feb 2023
Eligibility Forms
Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab Pembrolizumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab Pembrolizumab - Advanced or Metastatic Non-Small Cell Lung Cancer (Second or Subsequent Line) Pembrolizumab - First Line Treatment of MSI-H dMMR Metastatic Colorectal Cancer Pembrolizumab - First-line Treatment of Advanced Esophageal and Esophagogastric Junction Carcinoma Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma Pembrolizumab - Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma Pembrolizumab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Pembrolizumab (Adult and Pediatric) - Relapsed cHL Post-Autologous Stem Cell Transplant or ASCT Ineligible Pembrolizumab (Adult Who Failed Prior Brentuximab Vedotin) - Relapsed cHL Post-ASCT or ASCT Ineligible Pembrolizumab - In Combo w Carboplatin and Paclitaxel for First-Line Metastatic Squamous NSCLC Pembrolizumab - In Combo w Platinum and Pemetrexed for First Line Metastatic Non-Squamous NSCLC Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast CancerPatient Info Sheet
Jan 2023
What it is used for
- For treating certain types of cancers such as skin (called melanoma), non-small cell lung, head and neck, renal cell (kidney), colorectal, endometrial, cervical, bladder or urinary tract, breast, esophageal and others. It is also used to treat some types of lymphomas.
- Pembrolizumab is an immunotherapy drug. For more information on immunotherapy, click here.